Improving health outcomes with access to critical biomarkers for patient management
Our breakthrough High-Definition PCR (HDPCR™) multiplexing platform has the power to enable transformative genomic solutions. Our products provide physicians and lab partners faster results for improved decision making and better outcomes.
MAKING AN IMPACT
In oncology and genomics via easy to implement, cost-effective workflows, including reagent kits and cloud based software.
Multiplexing compared to conventional dPCR. Enables unprecedented coverage of clinically relevant biomarkers per the National Comprehensive Cancer Network (NCCN).
< 24 HOUR
Turnaround with minimal hands on time. Automated interpretation enabled by ChromaCode Cloud.
Hardware/software install. Highly scalable. Broad regulatory compliance (HIPAA, HITRUST, ISO 13485, GDPR).
Margins for lab partners enabled by low COGS, and higher throughput compared to conventional dPCR.
Multiplexing the way it should be
Enhance your lab’s molecular profiling capabilities with our HDPCR technology and instrument agnostic platform. With this simplified solution you can bring multi-analyte, multi-well, high content assays for oncology and other genomic applications to your lab.
HDPCR pairs proprietary innovations in chemistry and software to deliver the highest level of multiplexing, previously impossible using digital PCR (dPCR).
1.9 million patients in the US, and up to 19 million patients worldwide could benefit annually from tumor profiling. HDPCR multiplexes comprehensive DNA and RNA variants at a level previously not possible using dPCR by offering a simpler, high-margin alternative to NGS.
The platform allows for the customization of assays for pharma applications.
HDPCR for Minimal Residual Disease (MRD)*
3.3M US patients could benefit annually from MRD testing and this number is expected to grow to 6.7M patients. HDPCR personalized MRD assays provide rapid results with comparable sensitivity to NGS but at a significantly reduced cost.
HDPCR can be decentralized in the community to deliver rapid-turnaround, cost-effective assays for repeat testing applications including monitoring for treatment response and resistance, disease recurrence, and transplant rejection monitoring. The annual testing opportunity for transplant rejection monitoring is 1.6M tests in the US and 5M tests worldwide.
How we compare with other technologies
SIMPLE, RAPID, COMPREHENSIVE
“ChromaCode’s HDPCR and their technology platform, ChromaCode Cloud, streamlines both data generation and data analysis. This has allowed rapid validation and deployment of assays at scale in our laboratory.”
Dr. Bharat Thyagarajan, MD, Ph.D., MPH
Professor and Bittner Chair of Cancer Research, Director,
ARDL and MPG, University of Minnesota Medical School